New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

AbbVie Inc.

ABBV

Healthcare Drug Manufacturers General

AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024.

Revenue
+10.3%
EPS
+2,270.0%
Free cash flow
+9.97%
Total debt
+17.7%

Quarter to September 2026, against a year earlier

288.54 5.03 +1.77%
Market cap
$501.2B
P/E
48.8×
Fwd P/E FY26e
37.6×
Dividend yield
2.44%
F-score
8/9
ROIC
20.2%
Net debt / EBITDA
2.6×
Payout ratio
1.2×

Ratios over time FY16 to FY25

Returns on capital

ROIC was 16.0% in FY25, against a low of 7.83% in FY20. ROE, at 6,155.9%, is far above it because equity is small against the capital the business uses.

ROEROIC
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
ROE138.8%109.1%−339.6%−94.9%187.4%80.9%72.0%34.8%61.6%6155.9%
ROIC16.6%18.3%16.8%43.6%7.8%13.6%15.9%14.0%8.8%16.0%

Debt

Net debt is 2.59× a year’s EBITDA.

Net debt / EBITDA
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Net debt / EBITDA2.9×2.5×4.0×1.8×4.3×2.5×2.0×1.8×2.8×2.6×

Cash cycle, in days

Customers pay in 75 days, inventory is held 99 days and suppliers are paid in 696. Suppliers fund 522 days of working capital.

Cash cycleDays to pay suppliersDays to be paid
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Cash cycle−429−381−428−432−329−345−387−400−529−522
Days to pay suppliers587530564581478475532548690696
Days to be paid68666060706571757175

Per share, from FY16

Since FY16, per share: free cash flow has grown 10.7% a year; revenue has grown 9.09% a year.

Free cash flowRevenueBook value
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Free cash flow1.0×1.5×2.1×2.1×2.5×3.1×3.4×3.1×2.5×2.5×
Revenue1.0×1.1×1.3×1.4×1.7×2.0×2.1×1.9×2.0×2.2×
Book value1.0×1.1×−1.9×−1.9×2.7×3.1×3.4×2.1×0.7×−0.6×
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
96.82 74.04 58.54 24.57 20.99 37.47 16.77 25.75 29.91 17.19
Piotroski F-Score
8 5 5 8 6 4 7 7 5 6
P/S ratio
6.61 5.58 5.20 4.95 4.26 3.90 3.94 4.34 5.57 3.95
Altman Z-Score
2.31 1.87 1.98 2.30 1.85 1.31 2.19 2.24 2.44 2.05
P/FCF ratio
22.69 17.63 12.81 11.86 10.90 10.64 10.27 11.11 16.65 15.43
Altman Z″-Score (non-manufacturers)
(0.34) (0.35) 0.46 1.09 0.69 0.43 3.56 0.74 1.66 1.88
Beneish M-Score
(2.85) (3.08) (3.08) (2.84) (2.72) (1.90) (2.92) (3.15) (2.73) (2.45)
P/Operating CF
77.46 44.60 59.45 38.72 47.22 36.80 40.04 41.88 60.78 65.69
P/B ratio
0.00 93.45 27.18 16.64 15.53 13.64 0.00 0.00 30.81 21.84
EV/Sales
7.63 6.67 6.06 5.88 5.45 5.59 4.75 5.32 6.54 5.13
EV/EBITDA
19.39 17.09 12.81 12.85 11.59 14.37 10.53 21.39 16.72 12.50
EV/FCF
26.18 21.08 14.92 14.09 13.94 15.26 12.37 13.63 19.58 20.06
Current Ratio
0.67 0.66 0.87 0.96 0.79 0.84 3.18 0.98 1.28 1.65
Net Debt/EBITDA
2.59 2.80 1.81 2.03 2.53 4.35 1.79 3.96 2.50 2.89
Debt/Equity
(20.91) 19.96 5.71 3.66 4.97 6.57 (8.17) (4.77) 7.33 7.95
ROE
6,155.88% 61.59% 34.82% 72.01% 80.90% 187.45% (94.86%) (339.62%) 109.09% 138.75%
ROA
3.11% 3.14% 3.52% 8.26% 7.77% 3.85% 10.62% 8.74% 7.76% 9.99%
ROIC
15.97% 8.79% 14.00% 15.87% 13.61% 7.83% 43.55% 16.76% 18.26% 16.65%
Return on Tangible Assets
(48.68%) (52.76%) 3,213.33% 305.23% (535.34%) 607.37% 21.36% 219.66% 71.89% 66.07%
Average Days of Receivables
75.13 70.75 74.96 70.76 64.80 70.30 59.56 60.00 65.82 67.74
Earnings Yield
1.03% 1.35% 1.71% 4.07% 4.76% 2.67% 5.96% 3.88% 3.34% 5.82%
Free Cash Flow Yield
4.41% 5.67% 7.81% 8.43% 9.18% 9.40% 9.74% 9.00% 6.00% 6.48%
Free Cash Flow per Share
10.07 10.08 12.48 13.69 12.42 10.07 8.62 8.30 5.91 4.05
Book value per Share
(1.82) 1.90 5.88 9.76 8.72 7.86 (5.52) (5.48) 3.19 2.86
Free Cash Flow
17,816.00 17,832.00 22,062.00 24,248.00 21,990.00 16,790.00 12,772.00 12,789.00 9,431.00 6,562.00
EV/EBIT
30.94 41.14 25.80 18.86 17.10 22.55 12.16 27.31 19.34 14.10
Other line items

Show all line items

Columns are period end dates · fundamentals updated Nov 18, 2026